Electrochemical Aptamer Sensor for CSF Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing cerebrospinal fluid (CSF) leaks are hindered by latency, the need for purified samples, and inaccuracy in detecting CSF in the presence of contaminants like blood or mucus, with no FDA-approved portable device for point-of-care detection.
Innovation Solution
A portable 'lab-on-a-chip' device using electrochemical-aptamer-based (E-AB) technology with wrinkled-film electrodes, capable of detecting CSF biomarkers in small sample volumes without pre-treatment, even in the presence of contaminants, through the use of custom-designed aptamers and a miniaturized electrochemical chip design.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional beta-2 transferrin immunofixation is used for CSF detection, then high sensitivity and specificity are achieved, but the method requires 3-7 days latency time and specialized laboratory equipment
Solution Approach 1:
The patent replaces the mechanical/electrophoretic separation system with an electrochemical detection system. The electrochemical-aptamer-based sensor directly detects beta-2 transferrin through redox reactions, eliminating the need for electrophoresis equipment and complex laboratory infrastructure, thereby enabling rapid point-of-care testing within minutes while maintaining high detection accuracy.
Solution Approach 2:
The patent changes the detection parameter from electrophoretic mobility to electrochemical signal. By using aptamers functionalized with redox-active groups that generate measurable electrochemical signals upon binding beta-2 transferrin, the system achieves rapid detection without requiring the time-consuming electrophoresis process, reducing diagnosis time from days to minutes.
2Measurement precision
If beta-2 transferrin detection is performed using electrophoresis, then high sensitivity is achieved, but the method requires adequate sample quantity (at least 1 mL) and sample purity
Solution Approach 1:
The patent replaces the volume-intensive electrophoresis system with a miniaturized electrochemical sensor platform. The sensor concentrates and detects beta-2 transferrin in small sample volumes (microliters) through direct electrochemical binding, eliminating the need for large sample quantities required by traditional electrophoresis methods.
Solution Approach 2:
The patent transitions from a two-dimensional electrophoretic separation approach to a three-dimensional electrochemical detection approach using nanoscale aptamer structures. This dimensional change enables highly sensitive detection in minimal sample volumes by utilizing the high surface-area-to-volume ratio of the electrochemical sensor surface.
3Measurement precision
If conventional CSF detection methods are used, then detection accuracy is maintained, but the methods show ambiguous results in samples contaminated by blood or mucus
Solution Approach 1:
The patent introduces aptamers as intermediary molecules that specifically bind beta-2 transferrin with high affinity and selectivity. These aptamers act as mediators that distinguish the target analyte from contaminants like blood and mucus, maintaining detection accuracy even in contaminated samples by selectively capturing beta-2 transferrin molecules.
Solution Approach 2:
The patent changes the binding mechanism from non-specific adsorption to specific molecular recognition. The aptamers undergo conformational changes upon binding beta-2 transferrin, producing distinct electrochemical signals that differentiate the target from contaminants, thereby maintaining accuracy in contaminated samples through parameter-specific detection.
4Ease of operation
If portable point-of-care devices are developed for CSF detection, then accessibility and speed are improved, but previous devices suffered from high false positive rates and required extensive sample pre-processing
Solution Approach 1:
The patent replaces complex mechanical pre-processing systems with a streamlined electrochemical detection system. The miniaturized sensor directly analyzes samples without requiring centrifugation, filtration, or other pre-processing steps, while the specific aptamer binding ensures high reliability and low false positive rates in the portable device format.
Solution Approach 2:
The patent uses aptamers as selective intermediaries that specifically recognize beta-2 transferrin in complex biological matrices. This specific molecular recognition eliminates cross-reactivity with contaminants and reduces false positives, enabling reliable point-of-care testing in portable devices without extensive sample preparation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid, accurate, and specific detection of CSF, reducing the risk of false positives/negatives and improving accessibility for prompt diagnosis of CSF leaks, with potential for low-cost, scalable, and high-sensitivity detection.
Implementation Method 1
The sensor may be incubated with an aptamer solution, wherein the aptamer solution comprises an aptamer sequence comprising a first end and a second end. The first end is functionalized by a redox agent to be sensitive to one or more molecules found in CSF
Implementation Method 2
portable devices for detecting cerebrospinal fluid in a sample through the use of aptamer solutions and wrinkled-film electrodes
Data Source
AI summary
A portable device for detection of cerebrospinal fluid (CSF) in a sample. The device may comprise a substrate and a sensor disposed on the substrate, the sensor comprising a sensing area. The sensor further comprises an aptamer solution comprising an aptamer sequence functionalized by a redox agent to be sensitive to the CSF biomarker and functionalized to attach to the sensor. The sensor may be configured to be sensitive to a CSF biomarker. The device may further comprise an electrochemical detection component operatively coupled to the sensor. When a sample containing an amount of the CSF biomarker is disposed on the sensing area of the sensor, the electrode may generate a detection signal to be transmitted to the electrochemical detection component. The electrochemical detection component may transmit the detection signal to the computing device.